LABT
Lakewood-Amedex Biotherapeutics
$0.24
−$0.05 (−16.84%)Oct 29, 2026
Key metrics
The numbers that frame LABT today
- Market cap
- $561.62K
- ROIC
- -29,672.3%
- Div yield
- 0%
- Debt / equity
- 0.0
Growth
Revenue and earnings trend for LABT
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about LABT
Is Lakewood-Amedex Biotherapeutics a good buy?
No. Lakewood-Amedex Biotherapeutics has poor quality. Growth looks poor. That could put pressure on the long-term business case.
What is the market capitalization of LABT?
Lakewood-Amedex Biotherapeutics's market capitalization is $561.62K.
Does LABT stock pay dividends?
Lakewood-Amedex Biotherapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for LABT?
Lakewood-Amedex Biotherapeutics's Debt / Equity ratio is 0.02.